Yu-Hung Kuo

Yu-Hung Kuo

Auto-generated profile, based on publicly available information

Yu-Hung Kuo

Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SLShih-Wei Lai
Shih-Wei Lai
YKYu-Hung Kuo
Yu-Hung Kuo
KLKuan-Fu Liao
Kuan-Fu Liao

18 March 2022 in Medicine
Verified
Journal Article
Open access
SLShih-Wei Lai
Shih-Wei Lai
Bing-Fang HwangBing-Fang Hwang
Bing-Fang Hwang
YKYu-Hung Kuo
Yu-Hung Kuo
CLChiu-Shong Liu
Chiu-Shong Liu
KLKuan-Fu Liao
Kuan-Fu Liao
Objective: The aim of the study was to investigate the risk of prostate cancer among people with gout and/or hyperuricemia who used allopurinol and who did not use allopurinol. Methods: We conducted a meta-analysis to identify the cohort and case-control studies by searching PubMed and Web of Science. We used the random-effects model to calculate the pooled risk ratio with 95% confidence interval for the risk of prostate cancer associated with allopurinol treatment. Results: There were 5 cohort studies and 2 case-control studies included in the meta-analysis. All 7 eligible studies were published between 2012 and 2021. The study period ranged from 8 to 13years. The number of study subjects ranged from 25,770 to 1,623,550. The age of study subjects ranged from 20 to 99years. Overall, allopurinol treatment was not associated with the risk of prostate cancer (risk ratio = 1.13, 95% confidence interval = 0.96-1.34 and P = .13). The heterogeneity was high between studies (I2 = 93%). Conclusions: Our meta-analysis reveals that no association can be found between allopurinol treatment and the risk of prostate cancer among people with gout and/or hyperuricemia. We propose that the inhibition of xanthine oxidase and the reduction of serum uric acid via allopurinol treatment do not affect the probability of developing prostate cancer. Further studies are needed to confirm our findings. Key Points:

1 December 2021 in Maturitas
Verified
Journal Article
Closed access
SLShih-Wei Lai
Shih-Wei Lai
YKYu-Hung Kuo
Yu-Hung Kuo
KLKuan-Fu Liao
Kuan-Fu Liao

1 January 2024 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PCPEIYING CHUNG
PEIYING CHUNG
KLKuan-Fu Liao
Kuan-Fu Liao
YKYu-Hung Kuo
Yu-Hung Kuo
SLShih-Wei Lai
Shih-Wei Lai
Objective: To assess the association between polycystic ovary syndrome and pancreatic cancer in Taiwan.Methods: We used the 2013–2020 claims data of Taiwan National Health Insurance Program. A case‐control study was performed, including female subjects 20 years or older with and without pancreatic cancer. Cases comprised female subjects diagnosed with pancreatic cancer, identified based on diagnosis codes. Controls were selected from female subjects without pancreatic cancer and matched to cases on age and comorbidities. Polycystic ovary syndrome was identified through diagnosis codes. A conditional logistic regression model was used to assess the association between polycystic ovary syndrome and pancreatic cancer, with results presented as odds ratio (OR) and 95% confidence interval (CI).Results: This case‐control study included 12,466 cases with pancreatic cancer and 49,864 matched controls. The proportions of polycystic ovary syndrome were 2.6% among cases with pancreatic cancer and 1.4% among controls without pancreatic cancer (p < 0.001). After controlling for confounding factors, the conditional logistical regression model revealed a statistically significant association between polycystic ovary syndrome and pancreatic cancer, with an OR of 1.38 (95% CI = 1.21–1.59, p < 0.001).Conclusion: This case‐control study reveals that there is a statistically significant association between polycystic ovary syndrome and pancreatic cancer. More studies are needed to provide robust evidence.

1 January 2026 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
SLShih-Wei Lai
Shih-Wei Lai
YKYu-Hung Kuo
Yu-Hung Kuo
KLKuan-Fu Liao
Kuan-Fu Liao
Objective: Hyperthyroidism is a common endocrine disorder, yet its association with gout remains unclear. This study aimed to examine the association between hyperthyroidism and gout in patients aged 20–84 years using real‐world data. Methods: We conducted a retrospective cohort study using the TriNetX federated health research network from 2006 to 2023. Patients aged 20–84 years were categorized into two groups: those with a diagnosis of hyperthyroidism (hyperthyroidism group) and those without (control group). Propensity score matching was performed based on demographics and comorbidities. A 1‐month lag period was applied to minimize detection bias. The primary outcome was newly diagnosed gout. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models implemented in the TriNetX “Compare Outcomes” module. Results: After propensity score matching and applying a 1‐month lag period, 82,051 patients in the hyperthyroidism group and 82,111 patients in the control group were included. During a 5‐year follow‐up period, 420 patients in the hyperthyroidism group and 227 patients in the control group developed gout, corresponding to crude event proportions of 0.512% and 0.276%, respectively. The Cox model revealed that hyperthyroidism was associated with a higher risk of gout (HR 1.890; 95% CI, 1.608–2.221). Conclusion: Hyperthyroidism is associated with an increased risk of gout, highlighting the need for clinical awareness of this potential comorbidity.